BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24864177)

  • 1. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
    Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
    Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plexiform neurofibromas in NF1: toward biologic-based therapy.
    Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
    Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
    Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
    Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
    Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
    Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic delay of NF1 in hemifacial hypertrophy due to plexiform neurofibromas.
    Overdiek A; Feifel H; Schaper J; Mayatepek E; Rosenbaum T
    Brain Dev; 2006 Jun; 28(5):275-80. PubMed ID: 16481142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
    Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
    Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
    Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plexiform neurofibromas.
    Korf BR
    Am J Med Genet; 1999 Mar; 89(1):31-7. PubMed ID: 10469434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-α for unresectable progressive and symptomatic plexiform neurofibromas.
    Kebudi R; Cakir FB; Gorgun O
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e115-7. PubMed ID: 23042022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.